Affinity Asset Advisors, LLC Protagonist Therapeutics, Inc Transaction History

Affinity Asset Advisors, LLC

$862 Million
Q3 2025

A detailed history of Affinity Asset Advisors, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 220,600 shares of PTGX stock, worth $18.7 Million. This represents 1.7% of its overall portfolio holdings.

Number of Shares

220,600

Previous 440,000 49.86%

Holding current value

$18.7 Million

Previous $24.3 Million 39.74%

% of portfolio

1.7%

Previous 4.08%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$49.7 - $67.42 $11 Million - $14.9 Million	220,600 New	220,600 $14.7 Million
Q2 2025 Aug 13, 2025	BUY	$40.89 - $56.37 $1.64 Million - $2.25 Million	40,000 Added 10.0%	440,000 $24.3 Million
Q1 2025 May 14, 2025	BUY	$35.09 - $59.76 $9.47 Million - $16.1 Million	270,000 Added 207.69%	400,000 $19.3 Million
Q4 2024 Feb 13, 2025	BUY	$38.51 - $48.43 $5.01 Million - $6.3 Million	130,000 New	130,000 $5.02 Million
Q1 2024 May 14, 2024	BUY	$21.79 - $32.15 $2.18 Million - $3.22 Million	100,000 New	100,000 $2.89 Million

Q2 2022 Aug 12, 2022	SELL	$7.06 - $25.52 $2.12 Million - $7.66 Million	-300,000 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$23.34 - $36.08 $1.37 Million - $2.12 Million	58,881 Added 24.42%	300,000 $7.1 Million
Q4 2021 Feb 11, 2022	BUY	$17.63 - $37.1 $4.25 Million - $8.95 Million	241,119 New	241,119 $8.25 Million
Q3 2021 Nov 12, 2021	SELL	$12.95 - $49.69 $1.81 Million - $6.96 Million	-140,100 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$25.57 - $44.88 $2.3 Million - $4.04 Million	90,100 Added 180.2%	140,100 $6.29 Million
Q1 2021 May 14, 2021	BUY	$19.02 - $31.15 $951,000 - $1.56 Million	50,000 New	50,000 $1.3 Million

Others Institutions Holding PTGX

# of Institutions

296

Shares Held

66.9M

Call Options Held

139K

Put Options Held

40.7K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $4.15B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.

Account

Affinity Asset Advisors, LLC Protagonist Therapeutics, Inc Transaction History